Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Antiviral Res. 2019 Mar 19;165:47–54. doi: 10.1016/j.antiviral.2019.03.006

Figure 8. The antiviral effect of NA and CpAMs on WT and GYF strains.

Figure 8.

HepG2 cells were transfected with 1.6 μg of pCMVHBV-WT (lanes 2–6) or pCMVHBV-GYF (lanes 7–11). 16 h later, the transfected cells were left untreated (control, lanes 2 and 7) or treated with the indicated compounds at subinhibitory concentrations. The treatment was refreshed every other day, and cells were harvested at day 4 post-treatment. The cytoplasmic capsid (A), encapsidated pgRNA (B), and core DNA (C) were analyzed. The intensities of core DNA signals were quantified and are presented as relative levels compared to the untreated samples (WT or GYF).